These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 35008821

  • 1. Entrectinib Induces Apoptosis and Inhibits the Epithelial-Mesenchymal Transition in Gastric Cancer with NTRK Overexpression.
    Sohn SH, Sul HJ, Kim BJ, Kim HS, Zang DY.
    Int J Mol Sci; 2021 Dec 30; 23(1):. PubMed ID: 35008821
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of MEK1/2 Forestalls the Onset of Acquired Resistance to Entrectinib in Multiple Models of NTRK1-Driven Cancer.
    Vaishnavi A, Scherzer MT, Kinsey CG, Parkman GL, Truong A, Ghazi P, Schuman S, Battistone B, Garrido-Laguna I, McMahon M.
    Cell Rep; 2020 Aug 04; 32(5):107994. PubMed ID: 32755586
    [Abstract] [Full Text] [Related]

  • 3. Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion-Positive Tumor Cells in a Brain Metastasis Model.
    Nishiyama A, Yamada T, Kita K, Wang R, Arai S, Fukuda K, Tanimoto A, Takeuchi S, Tange S, Tajima A, Furuya N, Kinoshita T, Yano S.
    Clin Cancer Res; 2018 May 15; 24(10):2357-2369. PubMed ID: 29463555
    [Abstract] [Full Text] [Related]

  • 4. Targeting TRK family proteins in cancer.
    Khotskaya YB, Holla VR, Farago AF, Mills Shaw KR, Meric-Bernstam F, Hong DS.
    Pharmacol Ther; 2017 May 15; 173():58-66. PubMed ID: 28174090
    [Abstract] [Full Text] [Related]

  • 5. Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells.
    Yuan CX, Zhou ZW, Yang YX, He ZX, Zhang X, Wang D, Yang T, Pan SY, Chen XW, Zhou SF.
    Drug Des Devel Ther; 2015 May 15; 9():1293-318. PubMed ID: 25767376
    [Abstract] [Full Text] [Related]

  • 6. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
    Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD, trial investigators.
    Lancet Oncol; 2020 Feb 15; 21(2):271-282. PubMed ID: 31838007
    [Abstract] [Full Text] [Related]

  • 7. Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC.
    Frampton JE.
    Drugs; 2021 Apr 15; 81(6):697-708. PubMed ID: 33871816
    [Abstract] [Full Text] [Related]

  • 8. Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers.
    Fuse MJ, Okada K, Oh-Hara T, Ogura H, Fujita N, Katayama R.
    Mol Cancer Ther; 2017 Oct 15; 16(10):2130-2143. PubMed ID: 28751539
    [Abstract] [Full Text] [Related]

  • 9. Induction of resistance to neurotrophic tropomyosin-receptor kinase inhibitors by HMGCS2 via a mevalonate pathway.
    Kato Y, Matsumoto M, Takano N, Hirao M, Matsuda K, Tozuka T, Onda N, Nakamichi S, Takeuchi S, Miyanaga A, Noro R, Gemma A, Seike M.
    Cancer Med; 2024 Jun 15; 13(12):e7393. PubMed ID: 38923428
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of EGFR and MEK surmounts entrectinib resistance in a brain metastasis model of NTRK1-rearranged tumor cells.
    Suzuki C, Nishiyama A, Arai S, Tange S, Tajima A, Tanimoto A, Fukuda K, Takumi Y, Kotani H, Takeuchi S, Yanagimura N, Ohtsubo K, Yamamoto N, Omori K, Yano S.
    Cancer Sci; 2022 Jul 15; 113(7):2323-2335. PubMed ID: 35363931
    [Abstract] [Full Text] [Related]

  • 11. NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line.
    Lee SJ, Li GG, Kim ST, Hong ME, Jang J, Yoon N, Ahn SM, Murphy D, Christiansen J, Wei G, Hornby Z, Lee DW, Park JO, Park YS, Lim HY, Hong SN, Kim SH, Kang WK, Park K, Park WY, Kim KM, Lee J.
    Oncotarget; 2015 Nov 17; 6(36):39028-35. PubMed ID: 26472021
    [Abstract] [Full Text] [Related]

  • 12. Acquired NF2 mutation confers resistance to TRK inhibition in an ex vivo LMNA::NTRK1-rearranged soft-tissue sarcoma cell model.
    Chen Y, Steiner S, Hagedorn C, Kollar S, Pliego-Mendieta A, Haberecker M, Plock J, Britschgi C, Planas-Paz L, Pauli C.
    J Pathol; 2024 Jun 17; 263(2):257-269. PubMed ID: 38613194
    [Abstract] [Full Text] [Related]

  • 13. Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.
    Farago AF, Le LP, Zheng Z, Muzikansky A, Drilon A, Patel M, Bauer TM, Liu SV, Ou SH, Jackman D, Costa DB, Multani PS, Li GG, Hornby Z, Chow-Maneval E, Luo D, Lim JE, Iafrate AJ, Shaw AT.
    J Thorac Oncol; 2015 Dec 17; 10(12):1670-4. PubMed ID: 26565381
    [Abstract] [Full Text] [Related]

  • 14. Evolving role of entrectinib in treatment of NTRK-positive tumors.
    Chawla N, Bui NQ, Seetharam M.
    Future Oncol; 2021 Aug 17; 17(22):2835-2846. PubMed ID: 33896226
    [Abstract] [Full Text] [Related]

  • 15. Sequential treatments with TRK inhibitors in a patient with NTRK fusion-positive sarcoma: A case report.
    Kubota Y, Kawano M, Iwasaki T, Itonaga I, Tsumura H, Kaku N, Tanaka K.
    Medicine (Baltimore); 2023 Dec 08; 102(49):e36232. PubMed ID: 38065851
    [Abstract] [Full Text] [Related]

  • 16. Investigation of neurotrophic tyrosine kinase receptor 1 fusions and neurotrophic tyrosine kinase receptor family expression in non-small-cell lung cancer and sensitivity to AZD7451 in vitro.
    Tatematsu T, Sasaki H, Shimizu S, Okuda K, Shitara M, Hikosaka Y, Moriyama S, Yano M, Brown J, Fujii Y.
    Mol Clin Oncol; 2014 Sep 08; 2(5):725-730. PubMed ID: 25054037
    [Abstract] [Full Text] [Related]

  • 17. Detecting and Targeting NTRK Fusions in Cancer in the Era of Tumor Agnostic Oncology.
    Rohrberg KS, Lassen U.
    Drugs; 2021 Mar 08; 81(4):445-452. PubMed ID: 33400240
    [Abstract] [Full Text] [Related]

  • 18. C-Type Lectin-Like Receptor 2 Suppresses AKT Signaling and Invasive Activities of Gastric Cancer Cells by Blocking Expression of Phosphoinositide 3-Kinase Subunits.
    Wang L, Yin J, Wang X, Shao M, Duan F, Wu W, Peng P, Jin J, Tang Y, Ruan Y, Sun Y, Gu J.
    Gastroenterology; 2016 May 08; 150(5):1183-1195.e16. PubMed ID: 26855187
    [Abstract] [Full Text] [Related]

  • 19. Entrectinib: a potent new TRK, ROS1, and ALK inhibitor.
    Rolfo C, Ruiz R, Giovannetti E, Gil-Bazo I, Russo A, Passiglia F, Giallombardo M, Peeters M, Raez L.
    Expert Opin Investig Drugs; 2015 May 08; 24(11):1493-500. PubMed ID: 26457764
    [Abstract] [Full Text] [Related]

  • 20. Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.
    Russo M, Misale S, Wei G, Siravegna G, Crisafulli G, Lazzari L, Corti G, Rospo G, Novara L, Mussolin B, Bartolini A, Cam N, Patel R, Yan S, Shoemaker R, Wild R, Di Nicolantonio F, Bianchi AS, Li G, Siena S, Bardelli A.
    Cancer Discov; 2016 Jan 08; 6(1):36-44. PubMed ID: 26546295
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.